PneumoniaNCT07888049
Neutrophil Monocyte Lymphocyte Ratios in Pediatric Chest Infections
An observational study of Pneumonia and Bronchiolitis, run by Assiut University.
Trial summary
This prospective cohort study aims to evaluate neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, and neutrophil-to-monocyte ratio in children with lobar pneumonia, bronchiolitis, and bronchopneumonia compared with healthy children. Read more about this study
- Who is it for?
- Ages 1 month to 12 yearsHealthy volunteers can take part
- Conditions the study is for
- Pneumonia, Bronchiolitis
- How many people
- 120 participants
- Where
- No sites listed yet
- Study dates
- 20 Oct 2026to 20 Mar 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 1 month to 12 years
- All sexes
- Healthy volunteers accepted
- Child
Study population: Children aged 1 month to 12 years with lobar pneumonia, bronchiolitis, or bronchopneumonia, and healthy children of similar age, presenting to Assiut University Children's Hospital.
Who may be able to join
- - Children aged 1 month to 12 years
- Clinical diagnosis of lobar pneumonia, bronchiolitis, or bronchopneumonia (for disease groups)
- Healthy children without acute illness (for control group)
- Written informed consent from parent or legal guardian
Who cannot join
- - Age less than 1 month or greater than 12 years
- Hospital-acquired infection
- Immunodeficiency
- Congenital heart disease
- Chronic lung disease
- Systemic steroid use during the preceding 2 weeks
- Death within the first 24 hours
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Value of Neutrophil, Monocyte, and Lymphocyte Ratios as Diagnostic and Prognostic Markers in Pediatric Chest Infections
This prospective cohort study aims to evaluate neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, and neutrophil-to-monocyte ratio in children with lobar pneumonia, bronchiolitis, and bronchopneumonia compared with healthy children.
Read the detailed description
Chest infections are a leading cause of pediatric morbidity. Complete blood count-derived inflammatory ratios such as neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, and neutrophil-to-monocyte ratio are simple and inexpensive parameters that may help in the assessment of children with respiratory infections.
This observational study will include four groups of children aged 1 month to 12 years: healthy controls, lobar pneumonia, bronchiolitis, and bronchopneumonia. Neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, and neutrophil-to-monocyte ratio will be calculated from complete blood count at admission.
- Conditions
- Pneumonia, Bronchiolitis
- Keywords
- Neutrophil-to-lymphocyte ratio, Monocyte-to-lymphocyte ratio, Pediatric chest infection, Pneumonia, Assiut
- Medical subject headings
- Pneumonia, Bronchiolitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Healthy Children | Healthy children without acute respiratory illness serving as controls. | |
| Lobar Pneumonia | Children with clinical and radiographic findings of lobar pneumonia. | |
| Bronchiolitis | Children younger than 2 years with clinical diagnosis of bronchiolitis. | |
| Bronchopneumonia | Children with clinical and radiographic findings of bronchopneumonia. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Neutrophil-to-lymphocyte ratio
Mean neutrophil-to-lymphocyte ratio calculated as absolute neutrophil count divided by absolute lymphocyte count.
Measured: Baseline
Secondary outcomes (4)
Monocyte-to-lymphocyte ratio
Mean monocyte-to-lymphocyte ratio calculated as absolute monocyte count divided by absolute lymphocyte count.
Measured: Baseline
Neutrophil-to-monocyte ratio
Mean neutrophil-to-monocyte ratio calculated as absolute neutrophil count divided by absolute monocyte count.
Measured: Baseline
Number of children requiring oxygen
Number of children who require supplemental oxygen during hospital stay.
Measured: At 14 days
Length of hospital stay
Mean length of hospital stay in days.
Measured: At 14 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Oct 2026
- Study start20 Oct 2026 (estimated)
- Primary completion20 Oct 2027 (estimated)
- Study completion20 Mar 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PneumoniaStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 120 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Rania Ashraf Gaber Abdelghany, Assiut University
- Investigators
- Mohamed H Ghazaly, prof, Study chair, Pediatrics Department, Assiut University Hospitals
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07888049
- Sponsor's protocol ID
- NLR-Chest-Assiut-2026
- Status last verified
- Oct 2026
- First submitted
- 15 Oct 2026
- Last updated
- 22 Oct 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Value of Neutrophil, Monocyte, and Lymphocyte Ratios as Diagnostic and Prognostic Markers in Pediatric Chest Infections
- ClinicalTrials.gov ID
- NCT07888049
- Acronym / sponsor ID
- NLR-Chest-Assiut-2026
- Conditions
- Pneumonia, Bronchiolitis
- Keywords
- Neutrophil-to-lymphocyte ratio, Monocyte-to-lymphocyte ratio, Pediatric chest infection, Pneumonia, Assiut
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 120 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 20 Oct 2026 (estimated)
- Primary completion
- 20 Oct 2027 (estimated)
- Study completion
- 20 Mar 2028 (estimated)
- First posted
- 22 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This prospective cohort study aims to evaluate neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, and neutrophil-to-monocyte ratio in children with lobar pneumonia, bronchiolitis, and bronchopneumonia compared with healthy children.
Detailed description
Chest infections are a leading cause of pediatric morbidity. Complete blood count-derived inflammatory ratios such as neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, and neutrophil-to-monocyte ratio are simple and inexpensive parameters that may help in the assessment of children with respiratory infections.
This observational study will include four groups of children aged 1 month to 12 years: healthy controls, lobar pneumonia, bronchiolitis, and bronchopneumonia. Neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, and neutrophil-to-monocyte ratio will be calculated from complete blood count at admission.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Healthy Children | – | –Healthy children without acute respiratory illness serving as controls. |
| Lobar Pneumonia | – | –Children with clinical and radiographic findings of lobar pneumonia. |
| Bronchiolitis | – | –Children younger than 2 years with clinical diagnosis of bronchiolitis. |
| Bronchopneumonia | – | –Children with clinical and radiographic findings of bronchopneumonia. |
Who may qualify
- Ages
- 1 month to 12 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
- Study population
- Children aged 1 month to 12 years with lobar pneumonia, bronchiolitis, or bronchopneumonia, and healthy children of similar age, presenting to Assiut University Children's Hospital.
Key inclusion criteria (4 listed)
- - Children aged 1 month to 12 years
- Clinical diagnosis of lobar pneumonia, bronchiolitis, or bronchopneumonia (for disease groups)
- Healthy children without acute illness (for control group)
- Written informed consent from parent or legal guardian
Key exclusion criteria (7 listed)
- - Age less than 1 month or greater than 12 years
- Hospital-acquired infection
- Immunodeficiency
- Congenital heart disease
- Chronic lung disease
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Neutrophil-to-lymphocyte ratio
Time frame: Baseline
Mean neutrophil-to-lymphocyte ratio calculated as absolute neutrophil count divided by absolute lymphocyte count.
4 secondary outcomes
Monocyte-to-lymphocyte ratio
Time frame: Baseline
Neutrophil-to-monocyte ratio
Time frame: Baseline
Number of children requiring oxygen
Time frame: At 14 days
Length of hospital stay
Time frame: At 14 days
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Pneumonia
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Not yet recruitingPhase 2/3
A Pivotal Safety and Immunogenicity GBS-NN/NN2 Vaccine Maternal Immunisation Trial
Streptococcus Agalactiae Infection, Neonatal Sepsis
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Enrolling by invitation
Personalized Ventilator Settings for Patients on ECMO
Acute Respiratory Distress Syndrome (ARDS), Extracorporeal Membrane Oxygenation
Not yet recruiting
Expanded Diagnostic Strategy in Older Adults Hospitalized With Community-Acquired Acute Respiratory Infection
Acute Respiratory Infection
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Mohamed H Ghazaly, prof study chair
Pediatrics Department, Assiut University Hospitals
Questions about this trial
What is this clinical trial studying?
An observational study of Pneumonia and Bronchiolitis, run by Assiut University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 22 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Rania A Gaber, Resident (+20 10 67454245, raniaashraf111997@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Neutrophil-to-lymphocyte ratio (time frame: Baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Oct 2026.